Carcinoma News and Research

RSS

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.

Scientists identify new biomarker for diagnosing cause of thyroid cancer

The expression of the protein CLIP2 provides information on whether a papillary thyroid carcinoma was induced by radiation or had a sporadic origin. With this discovery, scientists from the Helmholtz Zentrum München have identified a new biomarker for the diagnosis of the cancer cause.

7 Oct 2014

Bristol-Myers Squibb, MD Anderson partner to evaluate multiple immunotherapies

Bristol-Myers Squibb Company and The University of Texas MD Anderson Cancer Center today announced a novel clinical research collaboration to evaluate multiple immunotherapies, including Opdivo (nivolumab), Yervoy (ipilimumab) and three early-stage clinical immuno-oncology assets from Bristol-Myers Squibb, as potential treatment options for acute and chronic leukemia as well as other hematologic malignancies.

6 Oct 2014

Genoscience Pharma to present novel cancer therapeutic strategy at EORTC-NCI-AACR Symposium

Genoscience Pharma, a company focused on discovering and developing small molecules to treat cancer by targeting cancer stem cells, today announces that it will present data on its most promising candidate at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, in Barcelona, Spain, on November 18-21, 2014.

3 Oct 2014

Breast cancer survivor supports patients and survivors of breast cancer

Barbara Feigin, successful business owner and breast cancer survivor, wanted to find a unique and memorable way to honor other breast cancer survivors and those who have fallen to the disease so she decided to paint the 44,000 square-foot administrative building at her company MainStreet America pink.

1 Oct 2014

GSK reports 45% survival rate in phase III study of Tafinlar in BRAF V600E mutant metastatic melanoma

GSK today announced updated results for Tafinlar (dabrafenib) from a planned analysis of the phase III BREAK-3 study in 250 patients with BRAF V600E mutant metastatic melanoma.

30 Sep 2014

Combination therapy achieves greater progression-free survival, response rates in melanoma

Combination therapy with both BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib achieves greater progression-free survival and response rates than vemurafenib plus placebo in BRAF-mutation positive melanoma, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.

30 Sep 2014

Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients

AbbVie released interim results from an ongoing Phase 2 study of its investigational compound veliparib in combination with chemotherapy, which showed a 35 percent improvement (P-value=0.14) in progression-free survival (PFS) and a 30 percent improvement (P-value=0.21) in overall survival (OS) in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC).

30 Sep 2014

Lung-MAP, ALCHEMIST clinical trials offer innovative study designs for lung cancer patients

The recent launch of two clinical trials offer innovative study designs for patients with lung cancer. These clinical trials are the direct result of a National Cancer Institute sponsored workshop chaired by Drs. Fred R. Hirsch, Shakun Malik and Claudio Dansky- Ullman, that brought together the NCI Thoracic Malignancies Steering Committee, the US Food and Drug Administration, academicians, clinicians as well as industry and government stakeholders to discuss issues and challenges related to clinical trial design and biomarkers for lung cancer targeted-therapies.

29 Sep 2014

Study correlates HPV vaccine series completion among young US women

According to a recent study in the journal Human Vaccines & Immunotherapeutics, only 60% of young US women who received the first dose of the human papilloma virus (HPV) vaccine went on to complete the three-dose vaccine series.

29 Sep 2014

Oral afatinib significantly improves progression-free survival in patients with head and neck cancer

The tyrosine kinase inhibitor afatinib significantly improved progression-free survival compared to methotrexate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after failure of platinum-based chemotherapy, the results of a phase III trial show.

29 Sep 2014

Immature blood vessels linked to poor sunitinib response

Patients with clear-cell renal cell carcinoma with relatively mature blood vessels respond better to sunitinib and have fewer metastatic sites than those with immature vessels, a study has found.

22 Sep 2014

ICO-IDIBELL researchers identify 5 genes differentially expressed in colorectal tumors

Researchers at the Catalan Institute of Oncology-Bellvitge Biomedical Research Institute, led by David Garcia-Mollev- have identified 5 genes differentially expressed in normal accompanying cells in colorectal tumors.

17 Sep 2014

OGT to highlight NGS and FISH methods for tumour screening at BSGM 2014

Oxford Gene Technology, The Molecular Genetics Company, is inviting attendees of the British Society for Genetic Medicine annual conference to its seminar entitled ‘Approaches to tumour screening and therapy stratification: case studies in Non-Small Cell Lung Cancer’ on Monday 22nd September, 13.10-13.50, room 2N.

From Oxford Gene Technology 17 Sep 2014

3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

3SBio Inc., a leading biotechnology company based in China focusing on researching, developing, manufacturing and marketing biopharmaceutical products, announced today that it has entered into an exclusive license agreement with JenKem Technology Co., Ltd for the development, manufacturing and marketing in Mainland China of PEG-irinotecan, a long-acting polymer-drug conjugate which inhibits topoisomerase I (Topo-I).

17 Sep 2014

Specific blood test could indicate neoadjuvant treatment regimens for ESCC patients

A blood test may be beneficial in indicating neoadjuvant treatment regimens for patients with esophageal squamous cell carcinoma (ESCC), according to research presented today at the American Society for Radiation Oncology's 56th Annual Meeting.

16 Sep 2014

Cancer-fighting cocktail shows promising results for advanced cervical cancer

Combining a standard chemotherapy drug with a second drug that stops cells from dividing improves both the survival and response rates for those with advanced cervical cancer, a new study by UT Southwestern Medical Center cancer researchers finds.

16 Sep 2014

Researchers examine whether new drug offers added benefit for patients with chronic HCV

The drug simeprevir has been available since May 2014 for the treatment of adult patients with chronic hepatitis C infection.

9 Sep 2014

New immuno-oncology drug helps body's own immune system to fend off cancer

According to an August 25 Reuters report, the U.S. Food and Drug Administration is likely to approve Merck & Co.'s highly anticipated immuno-oncology drug, pembrolizumab, as a treatment for melanoma well ahead of a late October deadline.

8 Sep 2014

Genetic mutation caused by ultraviolet light is likely driving force behind human skin cancers

A genetic mutation caused by ultraviolet light is likely the driving force behind millions of human skin cancers, according to researchers at the Stanford University School of Medicine.

8 Sep 2014

Study finds no association between bra wearing and increased breast cancer risk

A population-based case-control study found no association between bra wearing and increased breast cancer risk among postmenopausal women, according to research published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

5 Sep 2014

Carcinoma News and Research

Further Reading

Scientists identify new biomarker for diagnosing cause of thyroid cancer

Bristol-Myers Squibb, MD Anderson partner to evaluate multiple immunotherapies

Genoscience Pharma to present novel cancer therapeutic strategy at EORTC-NCI-AACR Symposium

Breast cancer survivor supports patients and survivors of breast cancer

GSK reports 45% survival rate in phase III study of Tafinlar in BRAF V600E mutant metastatic melanoma

Combination therapy achieves greater progression-free survival, response rates in melanoma

Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients

Lung-MAP, ALCHEMIST clinical trials offer innovative study designs for lung cancer patients

Study correlates HPV vaccine series completion among young US women

Oral afatinib significantly improves progression-free survival in patients with head and neck cancer

Immature blood vessels linked to poor sunitinib response

ICO-IDIBELL researchers identify 5 genes differentially expressed in colorectal tumors

OGT to highlight NGS and FISH methods for tumour screening at BSGM 2014

3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

Specific blood test could indicate neoadjuvant treatment regimens for ESCC patients

Cancer-fighting cocktail shows promising results for advanced cervical cancer

Researchers examine whether new drug offers added benefit for patients with chronic HCV

New immuno-oncology drug helps body's own immune system to fend off cancer

Genetic mutation caused by ultraviolet light is likely driving force behind human skin cancers

Study finds no association between bra wearing and increased breast cancer risk

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News